Why Baker Hughes Company (BKR) Lagged Performance on Wednesday
We recently published an article titled . In this article, we are going to take a look at where Baker Hughes Company (NASDAQ:BKR) stands against the other stocks.
Wall Street's major indices finished in the green territory anew on Wednesday as worries about tariff policies and the Federal Reserve's independence tapered off following President Donald Trump's assurance that he had no intentions of ousting Jerome Powell.
The Nasdaq surged by 2.5 percent, the S&P 500 rose by 1.67 percent, while the Dow Jones increased by 1.07 percent.
Ten companies, on the other hand, led the highest declines, booking modest losses during the trading session.
In this article, we have identified Wednesday's 10 worst-performing stocks and detailed the reasons behind their lagging performance.
To come up with the list, we considered only the stocks with more than $2 billion in market capitalization and $5 million in trading volume.
A drilling rig on a remote oilfield, its tower silhouetted against a setting sunset.
Baker Hughes Company (NASDAQ:BKR) saw its share price decline by 6.44 percent on Wednesday to end at $35.89 each as investor sentiment was weighed down by the company's dismal earnings performance and cautious business outlook for the rest of the year.
In the first quarter of the year, Baker Hughes Company (NASDAQ:BKR) saw net income drop by 12 percent to $402 million from $455 million in the same period a year earlier, while revenues ended flat at $6.4 billion.
Looking ahead, the company tempered its outlook for the year amid macroeconomic challenges brought about by uncertainties in trade policies.
'We believe Baker Hughes is well-positioned to navigate near-term challenges and deliver sustainable growth in shareholder value,' said BKR Chairman and Chief Executive Officer Lorenzo Simonelli.
Overall BKR ranks 6th on our list of the worst performing stocks on Wednesday. While we acknowledge the potential of BKR as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than BKR but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: and .
Disclosure: None. This article is originally published at .
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
1 Energy Stock With a Dividend Yield Over 7% Right Now
MPLX has a much higher dividend yield than the average energy stock. The master limited partnership's payout is on a sustainable foundation. It has been growing its earnings and distribution at healthy rates, and should continue to do so. 10 stocks we like better than MPLX › The energy sector can be a great place for income investors to find higher-yielding options. The average energy stock in the S&P 500 has a yield of around 3% at its current share price, which is more than double the 1.3% yield of the broad market index. Many energy stocks have even higher yields. One of them is MPLX (NYSE: MPLX). The midstream energy company yields more than 7% right now. Here's why income investors will want to take a closer look at MPLX. A yield above 7% might seem like a higher-risk income stream at first glance. However, that's not the case with MPLX's payout. The master limited partnership (MLP) has a rock-solid financial foundation supporting its big-time distribution. MPLX has a diversified midstream operation that generates lots of stable cash flow backed by long-term contracts and government-regulated rate structures. It produced nearly $1.5 billion in distributable cash flow during the first quarter -- enough to cover its distribution by a comfortable 1.5 times. The MLP produced about $500 million in excess free cash flow during the period. That was enough money to cover its organic capital spending with room to spare. (Its net cash used in investing activities was about $364 million after adjusting for acquisitions.) MPLX also has a robust balance sheet. It ended the first quarter with a leverage ratio of 3.3. That's comfortably below the 4.0 or so ratio its stable cash flows can support. MPLX stands out among higher-yielding dividend stocks because it's growing at a healthy clip. Its adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) rose by 7% in the first quarter. Meanwhile, its distributable cash flow was up 8.5%. The company has been growing its earnings and cash flow at a nearly 7% compound annual rate since 2021. That strong growth, along with the company's top-notch financial profile, has allowed MPLX to increase its distribution at a 10.7% compound annual rate since 2021, including by 12.5% last year. The MLP has plenty more growth coming down the pipeline. It has secured several new investments this year. MPLX and its partners recently made a final investment decision to build the Traverse Pipeline, which should enter commercial service in 2027. It's also building two Gulf Coast fractionators and a liquefied petroleum gas (LPG) export terminal, expanding its BANGL pipeline, building the Blackcomb and Rio Bravo pipelines, and constructing two more natural gas processing plants. These projects have in-service dates through 2029, giving the MLP lots of visibility into its earnings growth. "We continue to anticipate mid-teen returns on these projects, which will support mid-single digit adjusted EBITDA growth," said CEO Maryann Mannen in the first-quarter earnings press release. "This growth is expected to allow us to reinvest in the business and support annual distribution increases in the future." MPLX also continues to use its strong balance sheet to make acquisitions. Early this year, it agreed to buy the 55% of the BANGL pipeline it didn't already own for $715 million, another 5% interest in the Matterhorn Express pipeline for $151 million, and a crude oil gathering system for $237 million. Given its low leverage ratio, it has ample financial flexibility to continue making bolt-on acquisitions as opportunities arise. These and future deals will further enhance its earnings growth rate, giving it more fuel to increase its distribution. MPLX is currently paying over 7%, which is much higher than the average energy stock and the S&P 500. The MLP's big-time payout is on a very sustainable foundation. Further, it should continue growing for the next several years. That makes it a great option for income-seeking investors as long as they are comfortable receiving the Schedule K-1 federal tax form the MLP sends them each year. Before you buy stock in MPLX, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and MPLX wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor's total average return is 988% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Matt DiLallo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. 1 Energy Stock With a Dividend Yield Over 7% Right Now was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs
Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 10 Best Growth Stocks Under $100 to Buy Now. HC Wainwright & Co., a leading investment bank, has initiated a 'Buy' rating for Travere Therapeutics, Inc. (NASDAQ:TVTX), with a price target of $30, signaling an upside of around 100%. This confidence in the company underscores its position in the pharmaceutical sector. The company has just announced plans to present three new abstracts underscoring the impact of FILSPARI (sparsentan) in rare kidney disease at the International Podocyte Conference, taking place in Hamburg, Germany. The findings of FILSPARI, showcasing advanced reductions in urinary BAFF and sC5b9, along with dips in the proinflammatory and profibrotic biomarkers, signal a step forward in the treatment of IgAN. A laboratory technician working on a solution of rare diseases, housed in a cholic acid capsule. With net sales of FILSPARI increasing 182% year-over-year and the successful approval of FILSPARI in Europe and the UK, analysts have little doubt about the company's potential. Since the major revenue contribution comes from FILSPARI, the rising popularity and increasing adoption among nephrologists mean that Travere Therapeutics, Inc. (NASDAQ:TVTX) can continue to leverage a product that is quite differentiated. Travere Therapeutics, Inc. (NASDAQ:TVTX) is a biopharmaceutical company incorporated in 2008. This California-based giant recognizes, develops, and commercializes therapies for people suffering from rare kidney and metabolic diseases in the United States. While we acknowledge the potential of TVTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
France says supports Harvard, welcomes foreign students
France's foreign minister on Saturday said his country supported students and staff at Harvard, after President Donald Trump tried to ban foreign students from the prestigious US university. "We stand with universities facing the threat of government control, restriction to their funding, constraints on their curricula or research projects," Jean-Noel Barrot said during a commencement address at the high-profile HEC business school in Paris. "We stand with Harvard faculty, with Harvard students, facing unjustified stress and anxiety right now," he added in English. "Should US courts uphold decisions to ban international students, France will offer (them) a safe place to complete their degrees," he said. Universities and research facilities in the United States have come under increasing political and financial pressure under Trump, including with threats of massive federal funding cuts. Harvard has been at the forefront of Trump's campaign against top American universities after it defied his calls to submit to oversight of its curriculum, staffing, student recruitment and "viewpoint diversity". A US court last week put a temporary stay on Trump's latest effort to stop foreign students from enrolling at Harvard. A White House proclamation a day earlier had sought to bar most new international students at Harvard from entering the country, and said existing foreign enrollees risked having their visas terminated. The US government has already cut around $3.2 billion of federal grants and contracts benefiting Harvard and pledged to exclude the institution from any future federal funding. France and the European Union are seeking to encourage disgruntled researchers to relocate from the United States to Europe. European Commission head Ursula von der Leyen said last month that the EU would launch a new incentives package worth 500 million euros ($580 million) to make the 27-nation bloc "a magnet for researchers". French President Emmanuel Macron in April unveiled plans for a funding programme to help national universities and other research bodies cover the cost of bringing foreign scientists to the country. ah/rmb
